初治HIV-1感染患者中，拉替拉韦与依非韦伦联合替诺福韦/恩曲他滨治疗的疗效：STARTMRK研究第192周的总体及亚组分析
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.
作者信息
DeJesus Edwin, Rockstroh Jürgen K, Lennox Jeffrey L, Saag Michael S, Lazzarin Adriano, Zhao Jing, Wan Hong, Rodgers Anthony J, Walker Monica L, Miller Michael, DiNubile Mark J, Nguyen Bach-Yen, Teppler Hedy, Leavitt Randi, Sklar Peter
机构信息
Orlando Immunology Center, Orlando, Florida, USA.
出版信息
HIV Clin Trials. 2012 Jul-Aug;13(4):228-32. doi: 10.1310/hct1304-228.
We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads.
我们从正在进行的STARTMRK研究中选取初治HIV感染患者，比较了4年使用替诺福韦/恩曲他滨联合拉替拉韦或依非韦伦进行抗逆转录病毒治疗的效果。在192周的时间里，无论基线人口统计学和预后因素如何，包括病毒载量高的患者，与依非韦伦相比，拉替拉韦都能产生持久且稳定的病毒抑制和免疫恢复效果。
Zotero 插件